Bruxism and Pelvic Floor Dysfunction in Young Women

March 10, 2026 updated by: Alime Buyuk, Akdeniz University

Bruxism and Pelvic Floor Dysfunction in Young Women: A Cross-Sectional Questionnaire Study Examining the Relationship Between Orofacial Parafunction and Pelvic Floor Symptoms

Bruxism and Pelvic Floor Dysfunction in Young Women

Study Overview

Status

Enrolling by invitation

Conditions

Intervention / Treatment

Detailed Description

Bruxism and Pelvic Floor Dysfunction in Young Women: A Cross-Sectional Questionnaire Study Examining the Relationship Between Orofacial Parafunction and Pelvic Floor Symptoms

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Female individuals aged 18-30 years

-Voluntary agreement to participate in the study and approval of the online informed consent form

Description

Inclusion Criteria:

  • Female individuals aged 18-30 years
  • Voluntary agreement to participate in the study and approval of the online informed consent form

For the bruxism group:

  • Self-reported teeth clenching and/or grinding behavior during wakefulness or sleep within the past 6 months
  • Presence of clinical findings supporting bruxism (e.g., tooth wear patterns, masseter/temporalis muscle tenderness) identified during a clinical examination conducted at the Faculty of Dentistry

For the non-bruxism group:

  • No self-reported teeth clenching or grinding behavior
  • Absence of clinical findings supporting bruxism upon examination

Bruxism classification will be performed in accordance with the current international consensus, based on self-report combined with clinical findings, within the framework of "probable bruxism" (Verhoeff et al., 2025).

Exclusion Criteria:

  • Diagnosed temporomandibular joint (TMJ) dysfunction or significant jaw pain syndromes
  • History of major pelvic surgery; early postpartum period (<1 year) or current pregnancy
  • Neurological disorders (e.g., multiple sclerosis, peripheral neuropathies)
  • Presence of active urogenital or colorectal infection/disease
  • Diagnosed pelvic floor pathologies (e.g., advanced pelvic organ prolapse, severe urinary/fecal incontinence)
  • Chronic use of opioids, anticholinergic agents, or muscle relaxants
  • Severe psychiatric disorders (e.g., diagnosed major depressive disorder, generalized anxiety disorder)
  • Receipt of any bruxism-related treatment within the past 6 months (e.g., occlusal splint therapy, botulinum toxin injections, intensive physiotherapy)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Bruxism Group
Women who has bruksizm
Diagnostic test: Questionnaire and Physical Exam
20 mins questionnaire survey
Non-bruksizm Group
Control group
Diagnostic test: Questionnaire and Physical Exam
20 mins questionnaire survey

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Bruxism Assessment Section
Time Frame: 6 months
Sleep and awake bruxism will be evaluated according to the bruxism diagnostic criteria established by the American Academy of Sleep Medicine (AASM) in 2023. Bruxism-related pain will be subjectively assessed using the Visual Analog Scale (VAS). The Visual Analogue Scale (VAS) is a 10-cm used to measure pain intensity, where 0 represents "no pain" and 10 represents the "worst imaginable pain. Patients mark their pain level, which is measured in cm or mm to determine the score.
6 months
Jaw Function Assessment Section
Time Frame: 6 months
Jaw function will be evaluated using the Jaw Functional Limitation Scale-20 (JFLS-20). The Jaw Functional Limitation Scale-20 (JFLS-20) scores range from 0 to 200 (or 0-10 average per item), with higher scores indicating more severe jaw functional limitation. It measures 20 items across three constructs-mastication, vertical mobility, and verbal/emotional expression-using a 0-10 scale, with 0 meaning "no limitation" and 10 meaning "severe limitation
6 months
Pelvic Floor Assessment Section
Time Frame: 6 months
Pelvic floor symptoms will be assessed using the Pelvic Floor Distress Inventory-20 (PFDI-20) and the relevant items of the Pelvic Pain Impact Questionnaire. The Pelvic Floor Distress Inventory-20 (PFDI-20) is a questionnaire measuring the severity of pelvic floor dysfunction, with total scores ranging from 0 to 300 (0 = no distress, 300 = maximum distress). It includes three subscales-POPDI-6, UDI-6, and CRADI-8-each scored from 0 to 100, calculated by multiplying the mean of answered items (0-4) by 25
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anxiety Assessment Section
Time Frame: 6 months
Anxiety levels will be assessed using the State-Trait Anxiety Inventory (STAI - State Anxiety Scale). The State-Trait Anxiety Inventory (STAI-S) assesses temporary, immediate, or situation-specific anxiety using a 20-item self-report questionnaire with 4-point Likert-type responses. Scores range from 20 to 80, with higher scores indicating higher levels of anxiety. A cutoff of 39-40 is often used for detecting clinically significant symptoms.
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Akdeniz University

Collaborators

Konya Necmettin Erbakan Üniversitesi
Bilecik Seyh Edebali Universitesi

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 16, 2026

Primary Completion (Estimated)

April 16, 2026

Study Completion (Estimated)

May 15, 2026

Study Registration Dates

First Submitted

February 23, 2026

First Submitted That Met QC Criteria

February 23, 2026

First Posted (Actual)

February 27, 2026

Study Record Updates

Last Update Posted (Actual)

March 12, 2026

Last Update Submitted That Met QC Criteria

March 10, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025/721-28686

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bruxism

Clinical Trials on Questionnaire and Physical Exam

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe